1,435,460 Shares in Baxter International Inc. $BAX Acquired by Tocqueville Asset Management L.P.

Key Points

• Tocqueville Asset Management acquired 1,435,460 Baxter International shares worth approximately $30.6 million, representing about 0.28% of the company. Institutional investors and hedge funds collectively own 90.19% of BAX.
• Analysts largely maintain a cautious outlook, with nine Hold, two Buy, and two Sell ratings; the stock has an average price target of $22.45.
• Baxter exceeded quarterly expectations with adjusted EPS of $0.56 versus $0.37 forecast and revenue of $2.96 billion, up 5.3% year over year. Shares opened at $26.61, near the upper half of their 52-week range.

Tocqueville Asset Management L.P. bought a new position in shares of Baxter International Inc. (NYSE:BAX - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,435,460 shares of the medical instruments supplier's stock, valued at approximately $30,604,000. Tocqueville Asset Management L.P. owned about 0.28% of Baxter International at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Basepoint Wealth LLC acquired a new position in shares of Baxter International during the fourth quarter worth $26,000. Imprint Wealth LLC acquired a new stake in Baxter International in the third quarter valued at $27,000. MUFG Securities EMEA plc acquired a new stake in Baxter International in the second quarter valued at $46,000. Los Angeles Capital Management LLC bought a new position in Baxter International during the 4th quarter worth $46,000. Finally, Versant Capital Management Inc raised its position in Baxter International by 552.2% during the 2nd quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier's stock worth $51,000 after purchasing an additional 2,043 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BAX has been the topic of a number of analyst reports. Stifel Nicolaus upped their price objective on shares of Baxter International from $19.00 to $24.00 and gave the company a "hold" rating in a research note on Tuesday, July 28th. Citigroup raised shares of Baxter International from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $17.00 to $28.00 in a research note on Friday, July 31st. UBS Group boosted their target price on shares of Baxter International from $19.00 to $25.00 and gave the company a "hold" rating in a report on Tuesday, July 28th. TD Cowen upped their price target on shares of Baxter International from $20.00 to $24.00 and gave the company a "hold" rating in a research report on Monday, July 27th. Finally, Barclays increased their price target on Baxter International from $25.00 to $27.00 and gave the stock an "overweight" rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Baxter International currently has an average rating of "Hold" and an average target price of $22.45.

Baxter International Stock Performance

Shares of BAX stock opened at $26.61 on Thursday. Baxter International Inc. has a one year low of $15.73 and a one year high of $30.00. The company has a market cap of $13.76 billion, a P/E ratio of -12.86, a P/E/G ratio of 3.92 and a beta of 0.60. The firm has a 50-day moving average of $23.40 and a 200-day moving average of $20.27. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32.

Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. During the same period last year, the business posted $0.59 earnings per share. Baxter International's revenue was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Equities research analysts forecast that Baxter International Inc. will post 2.04 EPS for the current fiscal year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be paid a dividend of $0.01 per share. The ex-dividend date is Friday, August 28th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International's dividend payout ratio (DPR) is presently -1.93%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source